Podcasts about Aegean

We embark on a summer sojourn to the Aegean to celebrate the creative energy of Athens. We discover the Museum of Cycladic Art, meet shoemaker Le Monde Béryl and talk craftsmanship with Anthologist.See omnystudio.com/listener for privacy information.

First up on the podcast, Contributing Correspondent Andrew Curry joins host Sarah Crespi to discuss a pair of Science papers on kinship and culture in Neolithic Anatolia. The researchers used ancient DNA and isotopes from 8000 to 9000 years ago to show how maternal lines were important in Çatalhöyük culture.   ●     E. Yüncü et al., Female lineages and changing kinship patterns in Neolithic Çatalhöyük, 2025 ●     D. Koptekin et al., Out-of-Anatolia: Cultural and genetic interactions during the Neolithic expansion in the Aegean, 2025   Next on the show, researchers were able to make a synthetic material that changes color in the same way squids do. Georgii Bogdanov, a postdoctoral researcher in the Department of Chemical and Biomolecular Engineering at the University of California, Irvine, talks about how his lab was able to discover the subcellular arrangement of proteins in the squid cells and mimic this structure synthetically using titanium dioxide deposition.   Finally, the latest book in our series on science and death. Books host Angela Saini talks with Tamara Kneese about her book Death Glitch: How Techno-Solutionism Fails Us in This Life and Beyond and whether our families can turn us into chatbots after we die.   This week's episode was produced with help from Podigy.  About the Science Podcast   Authors: Sarah Crespi; Andrew Curry; Angela Saini Learn more about your ad choices. Visit megaphone.fm/adchoices

First up on the podcast, Contributing Correspondent Andrew Curry joins host Sarah Crespi to discuss a pair of Science papers on kinship and culture in Neolithic Anatolia. The researchers used ancient DNA and isotopes from 8000 to 9000 years ago to show how maternal lines were important in Çatalhöyük culture.   ●     E. Yüncü et al., Female lineages and changing kinship patterns in Neolithic Çatalhöyük, 2025 ●     D. Koptekin et al., Out-of-Anatolia: Cultural and genetic interactions during the Neolithic expansion in the Aegean, 2025   Next on the show, researchers were able to make a synthetic material that changes color in the same way squids do. Georgii Bogdanov, a postdoctoral researcher in the Department of Chemical and Biomolecular Engineering at the University of California, Irvine, talks about how his lab was able to discover the subcellular arrangement of proteins in the squid cells and mimic this structure synthetically using titanium dioxide deposition.   Finally, the latest book in our series on science and death. Books host Angela Saini talks with Tamara Kneese about her book Death Glitch: How Techno-Solutionism Fails Us in This Life and Beyond and whether our families can turn us into chatbots after we die.   This week's episode was produced with help from Podigy.  About the Science Podcast   Authors: Sarah Crespi; Andrew Curry; Angela Saini Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Turkey's latest move to submit a new so-called maritime spatial plan to UNESCO laying claim to half of the Aegean Sea is once again putting the spotlight on its revisionist Blue Homeland doctrine, and raising questions about its commitment to maintaining calm in the region. Constantinos Filis, the director of the Institute of Global Affairs and a professor of international relations at the American College of Greece, joins Thanos Davelis as we take a closer look at this development, breaking down what it means for Greece and the sense of calm that has prevailed over the past few years in the Aegean. You can read the articles we discuss on our podcast here:Turkey draws line of marine influence right down the Aegean SeaAthens navigates the day after the US inserted itself into the wars in IsraelMiddle East conflict's intensity, duration to shape impact on Greek economy Shipping faces elevated risk, Strait of Hormuz closure loomsFM to visit Libya amid maritime tensions

Where in the world am I? Eurail Travel planning   Hi there, I'm Dr. Mary Travelbest. I'm in San Diego now, sharing my best travel ideas and working on another book for you to enjoy: 5 Steps to Solo Travel, Part C. I'm about to launch on a 90-day trip around the world.   Listener Story Spotlight I want to tell you about a listener named Kristen. Kristen loves to travel. She recently received a Fullbright Scholarship and took a trip with her husband and sons to a foreign country, Portugal, for several months. She's full of great travel ideas and will be helpful as I continue to travel and make my adventures more mobile. She's encouraging me to keep going in my travels and is a professor in Southern California. Quick fire FAQ: The FAQ for today is:  Do you find that air travel dries your sinuses? Do you get dry and scratchy throats afterward? Yes, it happens. Let's talk about how to rid yourself of this in advance.    How to avoid the dryness of airline flights? The answer:   My solution is Saline Nasal Spray. I bought the 1.5-oz size for $4.00, which will last my entire trip. Before you get dry sinuses, squirt some in each nostril and then relax as it goes to work. What are the ingredients? Water, sodium chloride, disodium phosphate, benzyl alcohol, sodium phosphate, and benzalkonium chloride. Water and salt. There are three ways to use it: Squeeze twice in each nostril, and it delivers a spray, a stream, and a drop upside down. Take your pick. 60-second confidence challenge   Advice for Active Seniors :  “There is no shame in prioritizing and slowing down vs. overdoing. Most injuries happen when people are rushing. “Go slower, arrive sooner” is a helpful mantra.”  (Ellen McCabe) If you like today's Confidence Challenge, Chapter 2 of my book dives deeper buy it on Amazon or https://www.5stepstosolotravel.com   See Book A for addressing all of these items.   Today's destination is Eurail Travel Planning I said: You are traveling in Europe in the Summer of 2025. You arrive in Athens, Greece, then go to Krakow, Warsaw, Poland, Estonia, Finland, Sweden, Norway, and Denmark, and end in Edinburgh, Scotland, where you leave the EU. You will travel for five weeks. How many days will you want to use the Eurail pass for trains and ferries? Plan the trip, including seat fees and senior discounts with these countries, and suggest other places that would be a good stopping point or worth seeing. I am a solo woman in my prime. Include a mention of the low-cost airlines that I should take when not on the train or ferry.   Answer:   1  Where a Eurail day genuinely saves you money Below is every leg: (a) scenic or pricey at full fare and (b) covered or discounted by the pass if the trip is a low-fare train, like under $10.regional hop, we skip the past day and just pay cash—why burn powder you might need later?    1  Day 3 Athens → Kalabaka  €3 IC seat  Sunset over Meteora cliffs—worth the four-hour train.  2  Day 5 Kalabaka → Thessaloníki  free (regional) No supplement, but one more travel day.  3  Day 9 Krakow → Oświęcim (return) free (regional) Auschwitz day trip; counts once.  4  Day 11 Krakow → Warsaw (EIP)  ~PLN 35 ≈ €8  High‑speed, mandatory seat.  5  Day 13 Warsaw → Gdańsk or Toruń (optional)  PLN 3 ≈ €0.70 Use if you “dive” north.  6  Day 16 Tallinn → Helsinki ferry  deck = free; cabin = ‑20 %  Tallink Silja It counts oas ne travel day.  7  Day 17 Helsinki → Tampere & back  €0–€6 VR seat  Eurail Pendolino; book in app.  8  Day 19 Helsinki o/night ferry → Stockholm  deck = free; cabin –20 % Same Tallink perk.  9  Day 21 Stockholm → Uppsala (return)  €0 (regional) Same‑day out‑and‑back.  10  Day 22 Stockholm → Gothenburg  ≈ €7 SJ seat  Eurail Community 3 h X2000.  11  Day 23 Gothenburg → Oslo  free No reservations.  12  Day 25 Oslo → Bergen  ≈ NOK 50 ≈ €4 seat Bergensbanen panorama.  13  Day 26 Bergen → Flåm train + Nærøyfjord boat  boat covered A rail‑and‑fjord combo.  14  Day 30 Copenhagen → Roskilde day‑trip  ≈ €9 seat  Eurail Vikings have & an easy return.  15  Day 32 Edinburgh → Inverness  £0–£5 seat UK still in the Eurail network.   * Fees are 2ᵈ ‑class, summer 2025 published rates.   Total Eurail travel days = 15 – the cap of the 15‑days‑in‑2‑months Senior Global Pass  2  What about the long, awkward gaps? Why wrestle with two‑day rail marathons when a 90‑minute hop costs less than your hostel?   Segment Suggested airline(s) Typical July fare if bought 3 mo ahead Thessaloníki ✈ Krakow Ryanair, Aegean €55–€85 Warsaw ✈ Tallinn airBaltic, LOT, Ryanair €45–€90 Bergen ✈ Copenhagen Norwegian, SAS €65–€110 Copenhagen ✈ Edinburgh easyJet, Ryanair, Norwegian €40–€80   Question: could you train Thessaloníki→Krakow via Budapest? Yes—but it burns 2‑3 pass days plus €30‑€45 in night‑train supplements. The low‑cost flight is simply cheaper and quicker.   3  Five‑week skeleton itinerary   Week Base & ideas Safety‑first extras for a 65‑yr‑old solo traveler  1 Athens 3 d – dawn Acropolis, Plaka food walk → train to Meteora 2 d (monastery sunsets) → Thessaloníki 2 d for Byzantine walls & waterfront. Central hotels near Syntagma & Aristotelous squares; use the eat taxi app after dark.  2 Fly to Krakow 3 d (+ Auschwitz) → Warsaw 2 d → optional day to Toruń or Gdańsk. Women‑only dorms at Greg & Tom (Krakow) and OkiDoki (Warsaw); trains arrive before dusk.  3 Fly to Tallinn 2 d → ferry to Helsinki 3 d with day‑trip to Tampere—Telliskivi creative city, Suomenlinna flat walks; Bolt taxis for late returns.  4 Night ferry to Stockholm 3 d (+ Uppsala) → train to Gothenburg 2 d → rail to Oslo 2 d. Stockholm hostel “City Backpackers” has curtained bunks; carry Rail Planner live‑trip link to share location.  5 Oslo‑Bergen rail & fjords 3 d → Fly to Copenhagen 3 d (+ Roskilde) → Fly to Edinburgh; finish with Highlands loop 4 d (Inverness, Aviemore hikes) before departure. Fjord cruise boats have good handrails; Scottish B&Bs offer single rooms beside stations.   4  Is the pass still worth it? That's $200-250 saved, plus the flexibility to reroute if wildfires, strikes, or your whims intervene.   5  Quick checklist before you lock it in Buy the Senior Global Pass (15 days/2 months) before prices rise.   Book the four trains with limited seats (EIP Poland, X2000 Sweden, Bergensbanen, Copenhagen reservations) as soon as reservations open—usually 60–90 days in advance.   Use the Rail Planner app to activate travel days on the morning you board; keep two blanks until the very end in case you shuffle plans.   Flights: watch Friday flash sales on Ryanair/Norwegian; they routinely drop

At the 6th Maritime Archaeology Graduate Symposium (MAGS) held in Ioannina, Greece, Professor Lucy Blue spoke with Radomír Tichý from the University of Hradec Králové, Max Šámal (Charles University of Prague) and Aleš Panáček (Archaeopark Všestary) about a series of expeditions called “Monoxylon”. Hear how a team of Czech experimental archaeologists successfully reconstructed and navigated a replica of an 8,000-year-old Neolithic logboat discovered with five other boats at La Marmotta, a submerged lakeshore settlement beneath Lake Bracciano near Rome. Based on the largest, made from an oak trunk measuring over 10 metres in length, it featured transverse reinforcements for hull stability.  Additional objects discovered suggest the use of sails and the presence of obsidian tools from Milos, support the idea that these boats facilitated long distance trade and travel.  The series of expeditions tested the seaworthiness of these ancient designs. Monoxylon IV was paddled by twenty-one crewmembers over 500 kilometres across the Aegean from the island of Samos to the Peloponnese demonstrating that Neolithic communities possessed not only the craftsmanship to fashion such sophisticated vessels, but also the navigational skills to undertake such maritime journeys. The voyages provided practical insights into early human migration, trade routes, and the spread of agricultural practices across the Mediterranean with a profound human story at the heart.  For more information on this project visit the website (https://www.monoxylon.cz/en/), watch the teaser trailer for the upcoming documentary movie (https://youtu.be/6FkAuzf759U?feature=shared) and visit the project YouTube channel (https://www.youtube.com/…524)

In these verses, Paul's final remarks teach us that God is full of mercy and that his saints are chosen from all walks of life and from all levels of society (1 Cor. 1:26–31). We find among Paul's companions a runaway slave (engaged in ministry), a restored backslider (now forgiven and full of zeal), a pastor (concerned for his flock), a doctor-turned-historian, and others who work with Paul in evangelism. The apostle Paul is able to accomplish his ministry only because of the faithfulness of many dear friends who have stuck by him and who've been helpful to him in his ministry. And in order to use them as an encouragement to the Colossians and to all the churches that would read this letter, he tells us a little bit about them. And it adds a very warm, personal touch to what is a very doctrinal letter. It also indicates to me something of the magnetism of his personality, and the deep, rich love of which he was capable, because of the fact that he had so many of these people with him for so many years, and they had such a deep loyalty and love for the man. Those who brought greetings (vv. 7–9) Two envoys Tychicus and Onesimus are two loyal and highly valued friends of the apostle Paul. They are envoys sent with the epistles to the Ephesians, Colossians and Philemon to inform and encourage the believers in those churches (Eph. 6:21–22). tychicus WAS THE MAN WITH A SERVANTS HEART.  hE came from the province of Asia and was one of Paul's companions. The name “Tychicus” means fortuitous or fortunate; and indeed he was fortunate. We don't know much about him; there isn't much said in the Bible. He's mentioned five times, and every time it's very, very brief. But we know one thing: he lived up to his name, because he was a fortunate man to be able to spend as much time, in fact, as many years as he did in the ministry with the apostle Paul. He was a close friend who later would wait for him at Troas when Paul travelled to Jerusalem at the end of his third missionary journey (Acts 20:4) fourteen years later. Paul regards Tychicus as wholly reliable and a witness to his state in prison.  He is a man with a servant's heart. He realizes this is a long journey. He's leaving his home, his job, his friends, the fellowship of his church;    when we see him, as Paul writes Colossians, he's still with Paul; he's still around. He's stuck by him for a long time now. He went to Jerusalem with him. It may be that he returned with him. He for sure is with him now in the imprisonment in Rome. And at the end of Titus chapter 3, verse 12, he says, “When I shall send Artemas unto thee, or Tychicus, be diligent to come to me to Nicopolis; for I have determined to spend the winter there.” Here's a loyal man. And you know what? He says, “I'm going to send him, Titus, to take your place,” either he or Artemas. We don't know which one he sent, but it may well have been Tychicus.   Now what Paul wanted was – Paul loved Titus. Titus was the pastor of the congregations in the island of Crete, and Paul wanted Titus to come and spend the winter with him. Paul knew it wasn't only the winter of the year, but it was the winter of his life; and Paul wanted the fellowship and the love of Titus. And so he said to Titus, “Look, if you'll come and meet me in Nicopolis and spend the winter with me, I will send this man Artemas, or this man Tychicus, to take care of your church.”   Now it's kind of an interesting thing. Here is a man who started out as a messenger, and wound up substituting for a very great man, the man by the name of Titus. The man with a servant's heart made himself available, and God used him in ways, I'm sure, he never dreamed possible.   Now later on, I want you to notice something: Paul wrote the last letter that we believe he wrote, 2 Timothy chapter 4, verse 12, and he says this, writing to Timothy: “And Tychicus have I sent to Ephesus. The cloak that I left at Troas” – I'm glad he has that same problem that all of us have; he left his coat somewhere. “The cloak that I left at Troas with Carpus, when you come, would you please bring it, and my books, and especially the parchments?” Good to know he's human, isn't it? He left almost everything there. So he says, “When you come, will you bring all that stuff I left over there?”   Now you see, what he's saying here is, “Timothy, I want you to come and be with me; I need you. And in order that you can come and be with me, I know you'll have to leave your congregation in Ephesus so I'm going to send somebody to take your place.” And who is it? Tychicus again. He's making a career out of being an interim pastor, and he's filling in for some pretty, pretty high-class men: Titus and Timothy. He would reflect to both of those congregations the character of Paul, the life of Paul, the ministry of Paul; and they would love him because he would bring Paul to them. Now that's the kind of man he was. He was a messenger, and he was a pastor. In fact, he was anything Paul wanted him to be. We never find any bit of argument, we never find any bit of anxiety; we only find Tychicus doing what Paul told him to do.   But this is a faithful servant. He loves Paul. He's loyal. He'll be a messenger; he'll be a pastor; he'll be anything. And Paul here has in mind sending him with the letter to the Colossians. He isn't going to pastor, he's just going to be a delivery boy.   You say, “Well, that's not too tough.” Listen, if you knew what the trip was like from Rome to Laodicea and Colossae you might not say that. It's a long trip, a perilous trip. You had to cross Italy on foot, and then he had to sail the Adriatic, and then he had to cross Greece, and then he had to sail the Aegean. Then he had to walk, after he had landed at Miletus, up the steep Lycus River Valley to Laodicea and Colossae, and it wasn't easy; it was a very difficult journey. But Paul says, “He's going to come and he's going to bring the letter.”   And you know something? He didn't just have the letter of Colossians, he had another letter too. You say, “Well, what other letter did he have?” Well, I believe, if you look at Ephesians 6:21, it says; “But that you also may know my affairs, and how I do, Tychicus, a beloved brother and faithful minister in the Lord, shall make known to you all things whom I have sent unto you for the same purpose, that you might know our affairs, and that he might comfort your heart.” You see, that's almost an exact quote out of Colossians. So, now we know he doesn't have one letter, he's got two letters. Tucked somewhere in his robe is Colossians and Ephesians.   And, incidentally, the book of Ephesians, it was not just written to the Ephesians. In fact, we find many manuscripts; and in the beginning of Ephesians there is a blank where it says, “Paul an apostle of Jesus Christ, by the will of God, to the saints who are at blank.” You know why? This was a general letter to all the churches; it's just that one of the manuscripts we found happened to have Ephesus written in it. In the whole book of Ephesians there's not one allusion to a person in Ephesus.  And also had; he had another letter: Philemon. He had the letter to Philemon. And look at verse 9 of Colossians 4: “And along with Tychicus I'm sending Onesimus.” See? And Onesimus was the slave that was returning about whom the book of Philemon is written  The second thing he says – and this gets us into the thought that he is a servant's heart, “He is a faithful minister,” verse 7, and the word is diakonos, or servant. He is a faithful servant. He never attained prominence, he just served. He was an invaluable liaison between Paul and the churches; and he was faithful, he stuck with it. He was one of those 1 Corinthian 4 kind of stewards that was found faithful; he just did it, whatever it was. And you know something? There's no other way to get the work done, and Paul knew it. You've got to have people who have a servant's heart. He not only was a faithful servant of Paul but he was a fellow slave in the Lord. The first phrase has to do with Paul: “He is a faithful servant of mine, and a fellow slave in the Lord.” And Paul uses two different words. The first one is diakonos which just means servant. The second is sundoulos, which means bond slave. He is not a bond slave to Paul, don't confuse it. He's a bond slave to Jesus; he's just a willing servant to Paul. The New Testament words are important.     onesimus a man with a sinful past is a runaway slave who is the subject of the Epistle to Philemon.  Philemon was a convert of the apostle Paul. Verse 19 of Philemon he says that, “You owe to me your own self.” So he was a convert of Paul. And he's a very wealthy man; he owns some slaves. One of the slaves Philemon owned was a man named Onesimus, this man. But Onesimus didn't like living in Philemon's house, and he didn't like being a slave, so he ran away. And you know what a slave was to do when he ran away if he was caught? He was to give his life; he was executed. Runaway slaves were executed. But this one was willing to make the gamble, and he ran away, and he ran all the way to Rome. And you know what happened? Amazing thing: he ran right into the apostle Paul. And you know something? Just as the apostle Paul had led Philemon to Christ, the apostle Paul led Philemon's runaway slave to Christ. Isn't that amazing when you think there were two million people in Rome? Not so amazing when you see what God had in mind. Now Paul writes a letter, the letter of Philemon, and sends Onesimus back, and the letter says, “Say, Philemon, I know he ran away; but don't kill him. He may have gone away a slave; he's coming back a brother, and he's willing to serve you as a slave and a brother in Christ. So open your arms of love and take him, will you?” And so here's Tychicus with Philemon, the letter in his pocket, and Onesimus the slave walking beside him. Paul writes the letter to establish in Philemon's heart acceptance for a returning slave who's now a brotherHe has been recently converted and now serves Christ as Paul's ‘beloved brother' (v. 9). Paul is not interested in status or wealth, but in spirituality and faithfulness. Tychicus and Onesimus are both brothers to Paul through grace, men who were happy to help out and use their gifts under Paul's direction, accepting and recognizing that he was the Lord's servant. They are sent to ‘comfort hearts', that is, to encourage the Colossians to keep the faith and to obey the Word of God. And in the letter to Philemon he says, “Onesimus is” my very heart. Onesimus is my very heart. Those who sent greetings (vv. 10–14) Three messianic Jews (vv. 10–11) Aristarchus, Mark and Justus are fellow workers and long-term Jewish friends of Paul. These men worked with Paul for the glory of Christ in the local churches. They were team players who shared the same agenda as Paul for the church's growth and well-being and were not too busy ‘doing their own thing' to help out. Their ministry blessed Paul personally because he was encouraged by their friendship. The word ‘comfort' (v. 11) speaks of consolation and relief. We get the English word ‘paregoric' (‘a medicine that soothes pain') from the Greek used here. aristarchus is the man with a sympathetic heart. Now Aristarchus' name appears elsewhere in the New Testament in association with the town of Thessalonica. It's very likely that he came from that town. And at Ephesus, you remember Paul ministered at Ephesus for three years; and during those three years, Aristarchus was with him. And you remember when finally in Ephesus the riot broke out? When the riot broke out, Aristarchus and Gaius were seized by the mob, and Aristarchus found out what it was to be a prisoner. They recognized him as one of Paul's companions, and so they seized him. Now that's in chapter 19. Now Paul decides to go to Jerusalem. You know what happens? He takes Aristarchus along. So he goes on that trip. Paul gets on the boat. You remember he was captured as a prisoner in Jerusalem, then he was moved to Caesarea on the coast where he stayed as a prisoner. And then finally, in Acts 27, he gets on a boat to go to Rome to be tried in Rome, and he's a prisoner on the ship; and Acts 27:2 says when he got on the boat, Aristarchus was with him. Had Aristarchus been with him through all the imprisonment? Very possible. Very possible since the time he identified with Paul in the city of Ephesus, and escaped from the riot, and went to Jerusalem. From that time until now he has stayed with Paul; as a prisoner in Jerusalem, he hung around. Caesarea, he may have hung around. On the ship – and you remember what a ride that was. Read Acts 27 again. I mean that was something exciting, and he was there. Now here he is back in Rome. And guess who's there? Aristarchus. And Paul calls him “my fellow prisoner.” And the guy hasn't committed a crime, he just hangs around with criminals, so he spends his time in jail. came from Thessalonica (Acts 27:2) and he was with Paul during the riots at Ephesus (Acts 19:29). From Acts 20:4 we see that he also waited for Paul with Tychicus at Troas as Paul made his way back to Jerusalem. It is thought by some that he travelled with Paul as his slave or, alternatively, that he was taking a lift back home; whatever the truth is, he is also a prisoner in Rome at this time (Paul calls him ‘my fellow prisoner'). He was a volunteer willing to suffer for the kingdom of Christ. mark is the man with a second chance the cousin of Barnabas and the writer of the second Gospel. Twelve years prior to this, Mark and Barnabas had left Paul after a disagreement about whether Mark should accompany them on their second missionary journey. In Paul's opinion, Mark had been disloyal and cowardly when he deserted them at the end of their first missionary tour (Acts 15:36–41). Mark's relationship with Paul is now restored and he is fully engaged in the Lord's work and in full fellowship with the Lord's people. In 2 Timothy 4:13 Paul said that Mark was very useful to him for the ministry, thus assuring us that Mark's restoration to faithfulness was a permanent thing (see also 1 Peter 5:13). This is so encouraging as it tells us never to doubt the grace of God and his promise to keep us from falling. Mark is no longer a liability to Paul and is to be welcomed as a fully committed co-worker of Christ. Mark is forgiven both by God and by Paul. We should not withhold our love from those whom Christ has redeemed and restored. Restoration is a wonderful certainty because God promises it in Christ (Eph. 3:20–21; Jude 24). justus, the man with a strong commitment also called Jesus. His was a common name among the Jews. A man called by that name was nominated as a replacement apostle for Judas Iscariot (Acts 1:23), while another of the same name lived in Corinth and was a supporter of Paul (Acts 18:7). If the Justus of Colossians 4:11 is neither of these two (and that is what most commentators think) then he is mentioned only here in the New Testament and represents the ‘unknowns' in the Lord's service: those myriads of believers—ordinary people—with nothing particularly special to note about them, who yet have been chosen and given grace to be ‘fellow workers for the kingdom of God'. No matter how ‘unknown' believers may feel in their own little place, they contribute to the growth of the kingdom when they use their gifts and walk in obedience to Christ.        Mark 8:36 "For what will it profit a man if he gains the whole world, and loses his own soul?              John 14:6 Jesus said to him, “I am the way, the truth, and the life. No one comes to the Father except through Me. Have you trusted Him as your Savior? He can Save you if You ask Him based on His death, burial, and resurrection for your sins. Believe in Him for forgiveness of your sins today.               “And you shall know the truth, and the truth shall make you free.”  -John 8:32             Our mission is to spread the gospel and to go to the least of these with the life-changing message of Jesus Christ; We reach out to those the World has forgotten.              hisloveministries.podbean.com #HLMSocial hisloveministries.net https://www.instagram.com/hisloveministries1/?hl=en His Love Ministries on Itunes Don't go for all the gusto you can get, go for all the God (Jesus Christ) you can get. The gusto will get you, Jesus can save you. https://www.facebook.com/His-Love-Ministries-246606668725869/?tn-str=k*F             The world is trying to solve earthly problems that can only be solved with heavenly solutions

From the “Vertical Gas Corridor” to projects in the Eastern Mediterranean, Greece is stepping up its efforts on the energy front. This is placing it at the heart of exciting new developments that will link the East Med with Central Europe and even Ukraine, while drawing the attention of US energy giants like Exxon Mobil and Chevron. Tom Ellis, the editor in chief of Kathimerini's English Edition, joins Thanos Davelis as we break down some of the latest developments on the energy front, and look at what they mean for Greece and its partners in the region.You can read the articles we discuss on our podcast here:Greece on the regional energy mapGreece an ‘ideal connector' in the IMEC corridorGas to flow from Greece to Slovakia, UkraineGreek delegation heads to Egypt amid controversy Ankara eyeing Aegean in new exercise

Expert tour guides share advice for exploring the ancient ruins and seaside villages along Turkey's Aegean coast, the Renaissance wonders of Florence, the sun-drenched Tuscan countryside, and charming Danish towns and islands easily reached on day trips from Copenhagen. For more information on Travel with Rick Steves - including episode descriptions, program archives and related details - visit www.ricksteves.com.

Funny Birds with Catherine Deneuve, Lilo & Stitch, the unique perhaps crazy Universal Language, inspiring Wilding, the indy The Aegean and some Tom Cruise tangents.

Jacob Richardson's feature film debut The Aegean sees the Queensland based writer-director embrace the Grecian story of a widower, Hector (Costas Mandylor), who finds himself in the orbit of Khristos (Light), a refugee who finds himself in the waters of the Aegean Sea. As Khristos finds himself becoming embedded in Hector's life, he discovers an unexpected bond that will give him a sense of place and purpose that he was missing.In the above interview, Jacob talks about the personal connection to the narrative of The Aegean, how he worked with Costas Mandylor and Light to create their characters, and what it was like working with cinematographer Oliver Hay and composer Allister Harrison on the film. Jacob also talks about his journey from being a film critic to a filmmaker, and how each creative endeavour impacts on the other.The Aegean is released by Radioactive Pictures in Australian cinemas on 16 May 2025. Check your local cinema for screening dates.Follow us on Instagram, Facebook, and Bluesky @thecurbau. We are a completely independent and ad free website that lives on the support of listeners and readers just like you. Visit Patreon.com/thecurbau, where you can support our work from as little as $1 a month. If you are unable to financially support us, then please consider sharing this interview with your podcast loving friends.We'd also love it if you could rate and review us on the podcast player of your choice. Every review helps amplify the interviews and stories from storytellers to a wider audience. Hosted on Acast. See acast.com/privacy for more information.

Jacob Richardson's feature film debut The Aegean sees the Queensland based writer-director embrace the Grecian story of a widower, Hector (Costas Mandylor), who finds himself in the orbit of Khristos (Light), a refugee who finds himself in the waters of the Aegean Sea. As Khristos finds himself becoming embedded in Hector's life, he discovers an unexpected bond that will give him a sense of place and purpose that he was missing.In the above interview, Jacob talks about the personal connection to the narrative of The Aegean, how he worked with Costas Mandylor and Light to create their characters, and what it was like working with cinematographer Oliver Hay and composer Allister Harrison on the film. Jacob also talks about his journey from being a film critic to a filmmaker, and how each creative endeavour impacts on the other.The Aegean is released by Radioactive Pictures in Australian cinemas on 16 May 2025. Check your local cinema for screening dates.Follow us on Instagram, Facebook, and Bluesky @thecurbau. We are a completely independent and ad free website that lives on the support of listeners and readers just like you. Visit Patreon.com/thecurbau, where you can support our work from as little as $1 a month. If you are unable to financially support us, then please consider sharing this interview with your podcast loving friends.We'd also love it if you could rate and review us on the podcast player of your choice. Every review helps amplify the interviews and stories from storytellers to a wider audience. Hosted on Acast. See acast.com/privacy for more information.

In this solo episode, we journey to the Aegean island of Rhodes — once called Ophiussa, the serpent isle — to explore its forgotten role in anchoring Starfire Energy, housing Grail codes, and guarding the womb of Gaia's Solar Logos. From the Telchines to the Knights of St. John, from the fiery mountain of Tsambika to the cave temple of Lindos, this is a story written not in history books, but in soul memory and cosmic geometry.⚜️

"Saint Irene was the daughter of a princelet called Licinius; named Penelope by her parents, through a divine revelation she was brought to faith in Christ and at Baptism was renamed Irene. In her zeal for piety she broke in pieces all the idols of her father, who commanded that she be trampled underfoot by horses. But while she remained unharmed, one of the horses rose up and cast down her father, killing him. By her prayer she raised him to life again, and he believed and was baptized. Afterwards, in many journeyings, Saint Irene suffered torments and punishments for her faith, but was preserved by the power of God, while working dread miracles and converting many thousands of souls. At last she came to Ephesus, where she fell asleep in peace, in the first half of the fourth century. Two days after her death, her gravestone was found lifted off, and her grave empty. At least two churches were dedicated to St Irene in Constantinople, and she is the patroness of the Aegean island of Thera, which is commonly called Santorini, a corruption of "Saint Irene." (Great Horologion)   Note: The most famous Agia Irene church in Constantinople is not named after her, but for the Holy Peace (Greek Irene) of God, which is Christ.   The Prologue's account differs in several details. St Nikolai places St Irene in the Balkans in the town of Magedon, in apostolic times rather than the 3rd-4th century. In his account Irene learned the Christian faith from her teacher, Appelianus, and was baptised by the Apostle Timothy himself. He attributes the anger of Irene's father to her refusal to marry rather than her smashing the family idols (though of course she might have done both).

In this episode, we uncover the fascinating story of Shamgar, a lesser-known but mighty figure from Judges 3:31. Was he truly an Israelite judge or a foreign mercenary used by God? Join us as we explore his possible Hurrian or Canaanite roots, his ties to Egypt, and his epic stand against the Philistines, early Sea Peoples of Aegean descent. Through historical insights and biblical context, we reveal how Shamgar may have brought peace to Israel in a time of chaos. Don't miss this deep dive into ancient history, biblical mystery, and divine providence.   If you'd like to support "The History of the Bible", visit our Patreon Page at https://patreon.com/TheHistoryoftheBible. Your feedback is valuable to us! Share your thoughts and insights via our feedback form at https://forms.gle/AtzUReJ8gLuFYPaP8. Let us know how our podcast has impacted you or someone you know by filling out our impact form at https://forms.gle/jr4EdGsqCaFk4qZm8. If you have concerns about any information presented, please inform us via our correction form at https://forms.gle/PiMMkPnJFaa4j5p37.   #BiblePodcast, #BiblicalHistory, #OldTestament, #BookOfJudges, #Shamgar, #Philistines, #SeaPeoples, #AncientIsrael, #BiblicalArchaeology, #ChristianPodcast, #BibleStudyPodcast, #HiddenBibleFigures, #GodsWarrior, #HistoricalBible, #FaithAndHistory, #UnexpectedHeroes, #DivineProvidence, #BiblicalMystery, #Hurrians, #EgyptianMythology   Episode's Sources Bible, NIV Study Bible.  Bible, ESV Study Bible https://www.gotquestions.org/oxgoad-Bible.html https://www.biblicalarchaeology.org/daily/people-cultures-in-the-bible/who-were-philistines-where-did-they-come-from/ https://www.biblicalarchaeology.org/daily/people-cultures-in-the-bible/illuminating-the-philistines-origins/ https://www.worldhistory.org/Philistines/

In January of 1996 Greece and Turkey came close to conflict when the Imia crisis erupted. The US played a critical role in preventing a military escalation through Assistant Secretary of State Richard Holbrooke, and the US ambassadors in Athens and Ankara. Thomas Niles, the US ambassador in Athens at the time who passed away this week, spoke openly about the crisis in the years that followed, noting that the US had made a “big mistake” in not taking a position on Greek sovereignty in the Aegean. Tom Ellis, the editor in chief of Kathimerini's English Edition, joins Thanos Davelis as we look back at the Imia crisis of 1996, the US role in preventing a military confrontation, and its lasting legacy today.You can read the articles we discuss on our podcast here:Thomas Niles, US envoy during Imia crisis, dies at 85Stournaras: Crisis may be Europe's chanceU.S. Announces Deal to Share Ukraine's Mineral WealthUS and Ukraine sign agreement creating investment fund after months of negotiations

Welcome back to the Dirt Diaries! Today, we are going beyond the blade as we examine some of the weapons featured in the early scenes of power in Egypt and the Aegean. This is the weapons episode you have all been waiting for, as we travel back to the time of bronze and bloodshed.-Stay curiousWant more Dirt Diaries? Join patreon with all your history-loving friends!patreon.com/TheDirtDiariesTravel with me, my socials, and more!https://beacons.ai/dirtdiaries.tenn

A chilled island mix of aegean inspired melodic and deep house featuring tracks and remixes by Anthony Mea, Scott Diaz, Kaskade, T Markakis and more. LeyeT - Impossible Anthony Mea - Ginkla Scott Diaz - Philadelphia AM Five - Away Alexander Popov - Sunset Rays David Folkebrant - Above Ghon - Nimaya Meloko - Me Gusta (Nick Morgan Remix) T Markakis - Sensation John Monkman - Place To Be (String Mix) Killen - Mojo Kaskade - State Of Mind Proff - Love on a Real Train (Tangerine Dream Cover) Bona Fide - Sila Levorica - Moonsheild

The most famous armless statue of all time, ‘Venus de Milo' was discovered by a farmer on the Aegean island of Milos on 8th April, 1829, sparking an international bidding war that saw her eventually donated to the Louvre by Louis XVIII. The French had a particular interest in snapping up a new ancient treasure, having been forced to return many priceless artefacts to their original nations following Napoleon's defeat at Waterloo.  In this episode, Arion, Rebecca and Olly reveal the statue's original blingtastic paintwork; explain why Louis XVIII's obesity delayed its arrival in Paris; and ask what actually happened to Venus's arms… Image: https://flickr.com/photos/sey_alg9/ Further Reading: • ‘Venus de Milo: The Most Famous Armless Statue in the World' (HowStuffWorks, 2020): https://entertainment.howstuffworks.com/arts/artwork/venus-de-milo.htm • ‘How a peasant farmer found the Venus de Milo' (The National, 2020): https://www.thenational.scot/news/18365077.peasant-farmer-found-venus-de-milo/ • ‘The conspiracy behind this famous statue' (VOX, 2020): https://www.youtube.com/watch?v=gs1VWuQEd7Y Love the show? Support us!  Join 

Lee Haskell, chief commercial officer for Celestyal Cruises, talks with James Shillinglaw of Insider Travel Report about his company's recently completed season cruising the Gulf of Arabia. He also previews the season where Celestyal will sail two ships in the Aegean and Adriatic. For more Information, visit www.celestyal.com.  All our Insider Travel Report video interviews are archived and available on our Youtube channel  (youtube.com/insidertravelreport), and as podcasts with the same title on: Spotify, Pandora, Stitcher, PlayerFM, Listen Notes, Podchaser, TuneIn + Alexa, Podbean,  iHeartRadio,  Google, Amazon Music/Audible, Deezer, Podcast Addict, and iTunes Apple Podcasts, which supports Overcast, Pocket Cast, Castro and Castbox.  

On October 28, 2015, a boat meant for only a few dozen passengers capsized off the coast of Greece. Hundreds of refugees, forced in desperation onto the overloaded boat manned by armed smugglers, were tossed into the sea. The resulting loss of life, the largest in a single day during the crisis in the Aegean, shocked the world.After nearly a decade of research, interviews, and investigation, reporter Jeanne Carstensen has looked to capture every detail of the dramatic twenty-four hours. Her new book is: "A Greek Tragedy: One Day, A Deadly Shipwreck, And the Human Cost of The Refugee Crisis."

History sometimes has a habit of framing cultures as either heroes or villains, depending on the source. When it comes to Greek sources Herodotus "The Father of History", is kinda the go to when it comes to the period of antiquity. Every story needs a bad guy or a great evil to overcome, and when it comes to Herodotus his history was many times more fiction than fact. For the Greeks it was the vast and powerful Persian Empire coming to snuff out the light of the greek world. Weeeellllll...the Greeks were already doing a decent job of that themselves to be honest. While the first Persian Empire, established by the Acheamenid (Ack-a-men-id) Dynasty was central to the story of Greece "uniting", the Persians were across the Aegean doing some pretty incredible things. Founded by Cyrus the Great the Achaemenid Dynasty became the largest empire in the world during its time. Religious Tolerance, establishment of great road systems to carry trade and culture, the first mail system, a standardized monetary system based on the gold and silver, and a common language just to name a few. We owe a surprising amount of things in our modern world to this Empire. Tune in a find out just who were the Achaemenids and why maybe the Greeks kinda had it coming... Support the show

Santorini Cruise Season Threatened by Earthquakes is the top story on Monday, Travel and Cruise Industry Podcast, March 10, 2025. The Greek government is working overtime to make sure that Santorini, the “Jewel of the Aegean”, is ready for the start of cruise season. But after recent earthquakes have caused evacuations and damage to the port city, it remains to be seen if it will be ready in time. Also today, Tweetsie Railroad Opens; 2 Airlines Sue DOT; German Airline Strike; Flooded Twice On Same Cruise; Overboard Crew Member Found; and Lots more live today at 11 AM EST. CLICK HERE for video feed. #mondaytravelandcruiseindustrypodcast #travelandcruiseindustrynews #podcast #cruisenews #travelnews #cruise #travel #chilliescruises #chilliefalls #whill_us Thanks for visiting my channel. NYTimes The Daily, the flagship NYT podcast with a massive audience. "Vacationing In The Time Of Covid" https://nyti.ms/3QuRwOS To access the Travel and Cruise Industry News Podcast; https://cms.megaphone.fm/channel/trav... or go to https://accessadventure.net/ To subscribe: http://bit.ly/chi-fal I appreciate super chats or any other donation to support my channel. For your convenience, please visit: https://paypal.me/chillie9264?locale.... Chillie's Cruise Schedule: https://www.accessadventure.net/chillies-trip-calendar/ For your mobility needs, contact me, Whill.inc/US, at (844) 699-4455 use SRN 11137 or call Scootaround at 1.888.441.7575. Use SRN 11137. YouTube: https://www.youtube.com/ChilliesCruises Facebook: https://www.facebook.com/chillie.falls X: https://x.com/ChillieFalls Learn more about your ad choices. Visit megaphone.fm/adchoices

In 416BC, during the Peloponnesian War between Athens and Sparta, the island of Melos was a non-combatant. Strategically located in the middle of the Aegean, The Athenians arrived and demanded Melos surrender and thus be absorbed into their empire. The Melians refused, and so one of the most famous and influential passages in Thucydides' history as recounted by the delegates of Athens: ‘the strong do what they have the power to do and the weak accept what they have to accept.' We are returning to an era of empires asserting their dominance, and so joining to discuss Ukraine and its implications for Europe is historian and writer Philip Blood, author of Putin's War as we discuss the war over the past three years and what can be done in the future. As a brief little bonus for you, Tessa Dunlop joins to discuss the war as she launches a new podcast blending politics with history. Philip Blood Links Putin's War, Russian Genocide, Edited by Philip Blood Fallout on Ghost - Writings on Ukraine from Philp and team Philip on X Tessa Dunlop Links Where Politics Meets History Aspects of History Links Latest Issue out - Annual Subscription to Aspects of History Magazine only $9.99/£9.99 Ollie on X Aspects of History on Instagram Get in touch: history@aspectsofhistory.com Learn more about your ad choices. Visit podcastchoices.com/adchoices

Turkey's Erdogan has once again played up his country's importance on the world stage - especially when it comes to defense issues - telling Europeans that their security is “unthinkable without Turkey.” These comments come despite Ankara's well documented and aggressive moves in the region, from the Aegean and the Eastern Mediterranean to the Caucasus. Michael Rubin, the director of policy analysis at the Middle East Forum and a senior fellow at the American Enterprise Institute, joins Thanos Davelis to discuss what Europe and countries in the region like Greece can do to address the challenge Turkey poses today.You can read the articles we discuss on our podcast here:Greece Must Match Turkey's AggressivenessTurkey's growing defense industry deepening ties with European powersItalian research vessel departs Crete amid energy project uncertaintyGeopolitics freeze payments for Greece-Cyprus linkupTurkish Cypriot minister says UN meeting will lead nowhere

New Hero In Town by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/5742-new-hero-in-townLicense: http://creativecommons.org

He was born sometime in the mid-fourth century on an island in the Aegean. For a time he lived successfully in the world, receiving a good education in Constantinople, then serving for a time for the Prefect of the Praetorium. But, becoming aware of the vanity of worldly things, he answered Christ's call, gave away all his goods to the poor and entered a monastery in Syria. After four years in obedience, he came to feel that the security of monastic life was inconsistent with the Gospel command to take no thought for the morrow; so he withdrew to the desert, taking with him only his garment and the Book of the Gospel. There he lived alone for seven years.   At the end of this period he set out on an apostolic mission to Mesopotamia, where he brought many to Christ: the city prefect Rabbula was converted after Alexander brought down fire from heaven, and a band of brigands who accosted the Saint on the road were transformed into a monastic community. He finally fled the city when the Christians there rose up demanding that he be made bishop. He once again took up a solitary life in the desert beyond the Euphrates, spending the day in prayer and part of the night sheltered in a barrel. There he remained for forty years. His holiness gradually attracted more than four hundred disciples, whom Alexander organized into a monastic community. Each disciple owned only one tunic, and was required to give away anything that they did not need for that day. Despite this threadbare life, the monastery was able to set up and run a hospice for the poor!   Alexander was perplexed as to how the admonition Pray without ceasing (1 Thess. 5:17) could be fulfilled by frail human flesh, but after three years of fasting and prayer, God showed him a method. He organized his monks into four groups according to whether their native language was Greek, Latin, Syriac or Coptic, and the groups prayed in shifts throughout the day and night. Twenty-four divine services were appointed each day, and the monks would chant from the Psalter between services. The community henceforth came to be known as the Akoimetoi, the Unsleeping Ones. (Similar communities later sprang up in the West, practicing what was there called Laus Perennis; St Columban founded many of these.)   Always desiring to spread the holy Gospel, Saint Alexander sent companies of missionaries to the pagans of southern Egypt. He and a company of 150 disciples set out as a kind of traveling monastery, living entirely on the charity of the villages they visited. Eventually they settled in some abandoned baths in Antioch, setting up a there a monastery dedicated to the unceasing praise of God; but a jealous bishop drove them from the city. Making his way to Constantinople, he settled there with four monks. In a few days, more than four hundred monks had left their monasteries to join his community. The Saint organized them into three companies — Greeks, Latins and Syrians — and restored the program of unsleeping prayer that his community had practiced in Mesopotamia. Not surprisingly, his success aroused the envy and anger of the abbots whose monasteries had been nearly emptied; they managed to have him condemned as a Messalian at a council held in 426. (The Messalians were an over-spiritualizing sect who believed that the Christian life consisted exclusively of prayer.) Alexander was sent back to Syria, and most of his monks were imprisoned; but as soon as they were released, most fled the city to join him again. The Saint spent his last years traveling from place to place, founding monasteries, often persecuted, until he reposed in 430, 'to join the Angelic choirs which he had so well imitated on earth.' (Synaxarion)   The practice of unceasing praise, established by St Alexander, spread throughout the Empire. The Monastery of the Akoimetoi, founded by a St Marcellus, a successor of Alexander, was established in Constantinople and became a beacon to the Christian world. 'Even though it has not been retained in today's practice, the unceasing praise established by Saint Alexander was influential in the formation of the daily cycle of liturgical offices in the East and even more so in the West.' (Synaxarion)

This episode digs into the new trend of tweens and teens reaching for anti-aging skincare, and the “Sephora Kids” phenomenon.  Coming at the topic from the derm POV with Dr. Aegean Chan - what are some of the skin concerns with this trend, and what should skincare regimes look like for this age group. And from the regulatory and legal standpoint, with Claire Bing of  Confiance Cosmetics Group - who's responsible for all of this and what do brands need to know (whether they're intentionally marketing to kids/teens or not). Interested in supporting the podcast? Please share, subscribe and write a review! If it's accessible, we also have a Patreon which you can find at patreon.com/theecowell

Scientists are warning that a massive volcanic eruption could happen way sooner than we think. Some of the world's most powerful volcanoes are showing signs of waking up, and experts are keeping a very close eye on them. Small earthquakes, rising magma, and gas emissions are all pointing to something big brewing underground. If one of these giants erupts, it could affect everything—flights, weather, and even global temperatures. The good news? Scientists are working hard to predict when and where it might happen. The bad news? Nature doesn't always play by the rules.

We’re heading to Greece’s second city, Thessaloniki. This offbeat metropolis on the Aegean coast has a rich gastronomic identity thanks to its diverse history at the crossroads of east and west. In 2021, its culinary prowess was recognised by Unesco as a “City of Gastronomy” within its Creative Cities Network. Join Monocle’s Claudia Jacob on a tour of this colourful and compact city that’s sure to slake your appetite.See omnystudio.com/listener for privacy information.

At the end of Eric Cline's bestselling history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C.: The Survival of Civilizations (Princeton UP, 2025), Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. After 1177 B.C. tells how the collapse of powerful Late Bronze Age civilizations created new circumstances to which people and societies had to adapt. Those that failed to adjust disappeared from the world stage, while others transformed themselves, resulting in a new world order that included Phoenicians, Philistines, Israelites, Neo-Hittites, Neo-Assyrians, and Neo-Babylonians. Taking the story up to the resurgence of Greece marked by the first Olympic Games in 776 B.C., the book also describes how world-changing innovations such as the use of iron and the alphabet emerged amid the chaos. Filled with lessons for today about why some societies survive massive shocks while others do not, After 1177 B.C. reveals why this period, far from being the First Dark Age, was a new age with new inventions and new opportunities. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

At the end of Eric Cline's bestselling history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C.: The Survival of Civilizations (Princeton UP, 2025), Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. After 1177 B.C. tells how the collapse of powerful Late Bronze Age civilizations created new circumstances to which people and societies had to adapt. Those that failed to adjust disappeared from the world stage, while others transformed themselves, resulting in a new world order that included Phoenicians, Philistines, Israelites, Neo-Hittites, Neo-Assyrians, and Neo-Babylonians. Taking the story up to the resurgence of Greece marked by the first Olympic Games in 776 B.C., the book also describes how world-changing innovations such as the use of iron and the alphabet emerged amid the chaos. Filled with lessons for today about why some societies survive massive shocks while others do not, After 1177 B.C. reveals why this period, far from being the First Dark Age, was a new age with new inventions and new opportunities. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

At the end of Eric Cline's bestselling history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C.: The Survival of Civilizations (Princeton UP, 2025), Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. After 1177 B.C. tells how the collapse of powerful Late Bronze Age civilizations created new circumstances to which people and societies had to adapt. Those that failed to adjust disappeared from the world stage, while others transformed themselves, resulting in a new world order that included Phoenicians, Philistines, Israelites, Neo-Hittites, Neo-Assyrians, and Neo-Babylonians. Taking the story up to the resurgence of Greece marked by the first Olympic Games in 776 B.C., the book also describes how world-changing innovations such as the use of iron and the alphabet emerged amid the chaos. Filled with lessons for today about why some societies survive massive shocks while others do not, After 1177 B.C. reveals why this period, far from being the First Dark Age, was a new age with new inventions and new opportunities. Learn more about your ad choices. Visit megaphone.fm/adchoices

Recent findings from the Anti-Defamation League's (ADL) Global 100 study reveal that while global antisemitism has surged across the world over the last decade, Greece is bucking this trend. In fact, it recorded the largest decrease in antisemitic attitudes globally, with a 19-point drop. Aykan Erdemir, the Senior Director for Global Research and Diplomatic Affairs at the ADL, joins Thanos Davelis to break down the key takeaways from the ADL's study, looking at this global trend of rising antisemitism, and contrasting it to the progress Greece has made over the last decade.You can read the articles we discuss on our podcast here:Greece makes strides in global fight against antisemitism, study findsUS air force looks to upgrade Cyprus airbase as humanitarian staging post for the Middle EastIonian, Aegean marine parks plan pushed to mid-2025

8/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. BRONZE AGE HITTITE BULL

2/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. BRONZE AGE HITTITE

5/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. 1932 ISHTAR GATE

4/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. BRONZE AGE CERAMIC HITTITE OR ASSYRIAN

3/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. 1932 BABYLON

6/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration./8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. BRONZE AGE HITTITE

1/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. 1700 BABYLON

GOOD EVENING: The show begins in Dayton, Tennessee where the decision is made to challnge the anti-Darwinian State legislature... Scopes Trial outdoors because of the heat . CBS EYE ON THE WORLD WITH JOHN BATCHELOR FIRST HOUR - SECOND HOUR (9:00-11:00) Extended interview with Brenda Wineapple, discussing "Keeping the Faith: God, Democracy, and the Trial That Riveted a Nation" The 1925 Scopes trial in Dayton, Tennessee Clarence Darrow's defense of John T. Scopes William Jennings Bryan's prosecution Impact on American values and ongoing cultural divisions Early 20th century context of racism, intolerance, and social change THIRD HOUR - FOURTH HOUR (11:00-1:00) Extended interview with Eric H. Cline, discussing "After 1177 B.C.: The Survival of Civilizations" Aftermath of the Late Bronze Age collapse Fall of Aegean and Eastern Mediterranean civilizations Transition through the First Dark Age Stories of resilience and transformation Reconfiguration of civilizations in an age of chaos Each book discussion spans eight 15-minute segments, allowing for in-depth exploration of these historical works and their contemporary relevance.

7/8: After 1177 B.C.: The Survival of Civilizations by  Eric H. Cline  (Author) https://www.amazon.ca/After-1177-B-C-Survival-Civilizations/dp/0691192138 At the end of the acclaimed history 1177 B.C., many of the Late Bronze Age civilizations of the Aegean and Eastern Mediterranean lay in ruins, undone by invasion, revolt, natural disasters, famine, and the demise of international trade. An interconnected world that had boasted major empires and societies, relative peace, robust commerce, and monumental architecture was lost and the so-called First Dark Age had begun. Now, in After 1177 B.C., Eric Cline tells the compelling story of what happened next, over four centuries, across the Aegean and Eastern Mediterranean world. It is a story of resilience, transformation, and success, as well as failures, in an age of chaos and reconfiguration. NDATED RESCUE OF ERECH, BABYLON

Today I talked to Anthony McElligott about The Last Transport: The Holocaust in the Eastern Aegean (Bloomsbury, 2024). The deportation of 1,755 Jews from the islands of Rhodes and Cos in July 1944, shortly after the last deportation from Hungary, was the last transport to leave Greece for Auschwitz and brought to a close the last significant phase of the genocide of Europe's Jews (notwithstanding the death marches). Within six weeks of their deportation, the Germans were retreating from Greece and the Balkans as Hitler's empire shrank. This last deportation is frequently acknowledged in Holocaust literature but its significance for our understanding of the Nazi genocide of the Jews remains largely overlooked. The timing of the transport, when it was clear to the German military elite that Nazi Germany had lost the war, raises important questions in relation to long-term ideological Nazi goals and the immediate contingency thrown up by war. Anthony McElligott, in this account of the last Greek transport of Jews to Auschwitz, tells a compelling story of this previously underexplored event and sheds light on an important aspect of the Holocaust through an in-depth study of one Eastern Mediterranean community. Roberto Mazza is currently a visiting scholar at the Buffett Institute for Global Affairs at Northwestern University. He is the host of the Jerusalem Unplugged Podcast and to discuss and propose a book for interview can be reached at robbymazza@gmail.com. Twitter and IG: @robbyref Website: www.robertomazza.org Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

Today I talked to Anthony McElligott about The Last Transport: The Holocaust in the Eastern Aegean (Bloomsbury, 2024). The deportation of 1,755 Jews from the islands of Rhodes and Cos in July 1944, shortly after the last deportation from Hungary, was the last transport to leave Greece for Auschwitz and brought to a close the last significant phase of the genocide of Europe's Jews (notwithstanding the death marches). Within six weeks of their deportation, the Germans were retreating from Greece and the Balkans as Hitler's empire shrank. This last deportation is frequently acknowledged in Holocaust literature but its significance for our understanding of the Nazi genocide of the Jews remains largely overlooked. The timing of the transport, when it was clear to the German military elite that Nazi Germany had lost the war, raises important questions in relation to long-term ideological Nazi goals and the immediate contingency thrown up by war. Anthony McElligott, in this account of the last Greek transport of Jews to Auschwitz, tells a compelling story of this previously underexplored event and sheds light on an important aspect of the Holocaust through an in-depth study of one Eastern Mediterranean community. Roberto Mazza is currently a visiting scholar at the Buffett Institute for Global Affairs at Northwestern University. He is the host of the Jerusalem Unplugged Podcast and to discuss and propose a book for interview can be reached at robbymazza@gmail.com. Twitter and IG: @robbyref Website: www.robertomazza.org Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/history

Today I talked to Anthony McElligott about The Last Transport: The Holocaust in the Eastern Aegean (Bloomsbury, 2024). The deportation of 1,755 Jews from the islands of Rhodes and Cos in July 1944, shortly after the last deportation from Hungary, was the last transport to leave Greece for Auschwitz and brought to a close the last significant phase of the genocide of Europe's Jews (notwithstanding the death marches). Within six weeks of their deportation, the Germans were retreating from Greece and the Balkans as Hitler's empire shrank. This last deportation is frequently acknowledged in Holocaust literature but its significance for our understanding of the Nazi genocide of the Jews remains largely overlooked. The timing of the transport, when it was clear to the German military elite that Nazi Germany had lost the war, raises important questions in relation to long-term ideological Nazi goals and the immediate contingency thrown up by war. Anthony McElligott, in this account of the last Greek transport of Jews to Auschwitz, tells a compelling story of this previously underexplored event and sheds light on an important aspect of the Holocaust through an in-depth study of one Eastern Mediterranean community. Roberto Mazza is currently a visiting scholar at the Buffett Institute for Global Affairs at Northwestern University. He is the host of the Jerusalem Unplugged Podcast and to discuss and propose a book for interview can be reached at robbymazza@gmail.com. Twitter and IG: @robbyref Website: www.robertomazza.org Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/german-studies

Today I talked to Anthony McElligott about The Last Transport: The Holocaust in the Eastern Aegean (Bloomsbury, 2024). The deportation of 1,755 Jews from the islands of Rhodes and Cos in July 1944, shortly after the last deportation from Hungary, was the last transport to leave Greece for Auschwitz and brought to a close the last significant phase of the genocide of Europe's Jews (notwithstanding the death marches). Within six weeks of their deportation, the Germans were retreating from Greece and the Balkans as Hitler's empire shrank. This last deportation is frequently acknowledged in Holocaust literature but its significance for our understanding of the Nazi genocide of the Jews remains largely overlooked. The timing of the transport, when it was clear to the German military elite that Nazi Germany had lost the war, raises important questions in relation to long-term ideological Nazi goals and the immediate contingency thrown up by war. Anthony McElligott, in this account of the last Greek transport of Jews to Auschwitz, tells a compelling story of this previously underexplored event and sheds light on an important aspect of the Holocaust through an in-depth study of one Eastern Mediterranean community. Roberto Mazza is currently a visiting scholar at the Buffett Institute for Global Affairs at Northwestern University. He is the host of the Jerusalem Unplugged Podcast and to discuss and propose a book for interview can be reached at robbymazza@gmail.com. Twitter and IG: @robbyref Website: www.robertomazza.org Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/jewish-studies

In the glittering Aegean of the 520s BC, Polycrates of Samos was a man of unmatched ambition and cunning—a tyrant who ruled the seas and defied the odds. But every rise has its fall. In this episode, we follow Polycrates' journey to his gruesome end, a story of hubris, betrayal, and the inevitable downfall of the man who thought he could cheat fate.Herodotus link:https://penelope.uchicago.edu/Thayer/E/Roman/Texts/Herodotus/3B*.htmlThis is a podcast by Dan Hörning and Bernie Maopolski.If you like what we do you can support the Fan of History project on https://www.patreon.com/fanofhistoryContact information:E-mail: zimwaupodcast@gmail.comhttp://facebook.com/fanofhistoryhttps://twitter.com/danhorninghttps://www.instagram.com/dan_horning/ Support the show and listen ad-free to all of the episodes, including episode 1-87. Click here: https://plus.acast.com/s/history. Hosted on Acast. See acast.com/privacy for more information.

News items read by Laura Kennedy include: Spectacular shipwreck bearing 10,000 ceramics lay untouched in Aegean for over a millennium (details) Ancient genomes reveal Bronze Age branching of Indo-European language groups (details) (details) Villa double the size of US White House revealed within ancient Assyrian capital (details)(details) 1,500-year-old Peruvian tomb holds teenage human sacrifices to family members (details) (details)